Evicenter
MarkdownMedical informationP&T meetings
Lonimecgene renparvovec (TSHA-102)

Rett syndrome

Launch
Not announced
Last updated
199 sources

Section 6 of 6

References

199 sources

  1. Abbott et al. (2024) (opens in a new tab)
  2. Acadia DAYBUE prescribing information (2026) (opens in a new tab)
  3. Acadia Pharmaceuticals Form 10-K (2026) (opens in a new tab)
  4. Amir et al. (1999) (opens in a new tab)
  5. Anderson et al. (2014) (opens in a new tab)
  6. Ben-Zeev et al. (2026) (opens in a new tab)
  7. Berry-Kravis et al. (2026a) (opens in a new tab)
  8. Berry-Kravis et al. (2026b) (opens in a new tab)
  9. Bienvenu et al. (2006) (opens in a new tab)
  10. Bisgaard et al. (2021) (opens in a new tab)
  11. Blue Shield of California (2023) (opens in a new tab)
  12. Boban et al. (2018) (opens in a new tab)
  13. Bond et al. (2025) (opens in a new tab)
  14. Buchanan et al. (2022) (opens in a new tab)
  15. Byiers et al. (2014) (opens in a new tab)
  16. CDA-AMC trofinetide reimbursement recommendation (2025) (opens in a new tab)
  17. CDA-AMC trofinetide reimbursement review (2025) (opens in a new tab)
  18. Cherchi et al. (2023) (opens in a new tab)
  19. Cherchi et al. (2024) (opens in a new tab)
  20. Choi et al. (2025) (opens in a new tab)
  21. ClinicalTrials.gov NCT00299312 (opens in a new tab)
  22. ClinicalTrials.gov NCT02738281 (opens in a new tab)
  23. ClinicalTrials.gov NCT04181723 (opens in a new tab)
  24. ClinicalTrials.gov NCT04279314 (opens in a new tab)
  25. ClinicalTrials.gov NCT04776746 (opens in a new tab)
  26. ClinicalTrials.gov NCT04988867 (opens in a new tab)
  27. ClinicalTrials.gov NCT05606614 (opens in a new tab)
  28. ClinicalTrials.gov NCT05898620 (opens in a new tab)
  29. ClinicalTrials.gov NCT06152237 (opens in a new tab)
  30. ClinicalTrials.gov NCT07480564 (opens in a new tab)
  31. Corchón et al. (2018) (opens in a new tab)
  32. Cosand et al. (2026) (opens in a new tab)
  33. Crosson et al. (2017) (opens in a new tab)
  34. Cuddapah et al. (2014) (opens in a new tab)
  35. Cutri-French et al. (2020) (opens in a new tab)
  36. Desnous et al. (2024) (opens in a new tab)
  37. Devidze et al. (2023) (opens in a new tab)
  38. Downs et al. (2009) (opens in a new tab)
  39. Downs et al. (2014) (opens in a new tab)
  40. Downs et al. (2016) (opens in a new tab)
  41. Downs et al. (2018) (opens in a new tab)
  42. Downs et al. (2019) (opens in a new tab)
  43. Downs et al. (2024) (opens in a new tab)
  44. EMA Daybu EPAR (2026) (opens in a new tab)
  45. EMA paediatric investigation plan decision (2025) (opens in a new tab)
  46. Epstein et al. (2016) (opens in a new tab)
  47. Fang et al. (2022) (opens in a new tab)
  48. FDA Innovative Designs for Clinical Trials of Cellular and Gene Therapy Products in Small Populations draft guidance (2025) (opens in a new tab)
  49. FDA Orphan Drug Designations and Approvals (2020) (opens in a new tab)
  50. FDA UNII NVK87P6NXW (opens in a new tab)
  51. Fehr et al. (2010) (opens in a new tab)
  52. Fehr et al. (2011) (opens in a new tab)
  53. Fonzo et al. (2020) (opens in a new tab)
  54. Freilinger et al. (2010) (opens in a new tab)
  55. Fu et al. (2020a) (opens in a new tab)
  56. Fu et al. (2020b) (opens in a new tab)
  57. Galán-Olleros et al. (2024) (opens in a new tab)
  58. Glaze et al. (2010) (opens in a new tab)
  59. Gold et al. (2024) (opens in a new tab)
  60. Greenwood Genetic Center (opens in a new tab)
  61. Guy et al. (2007) (opens in a new tab)
  62. Hagberg et al. (1983) (opens in a new tab)
  63. Haque et al. (2023) (opens in a new tab)
  64. Haque et al. (2024) (opens in a new tab)
  65. Haque et al. (2025) (opens in a new tab)
  66. Haque et al. (2026a) (opens in a new tab)
  67. Haque et al. (2026b) (opens in a new tab)
  68. Hendrie et al. (2011) (opens in a new tab)
  69. Hryniewiecka-Jaworska et al. (2025) (opens in a new tab)
  70. ICH E11A guideline (2024) (opens in a new tab)
  71. Jefferson et al. (2016) (opens in a new tab)
  72. Kaufmann et al. (2024) (opens in a new tab)
  73. Kaur and Christodoulou (2025) (opens in a new tab)
  74. Keeley et al. (2025) (opens in a new tab)
  75. Killian et al. (2016) (opens in a new tab)
  76. Killian et al. (2017) (opens in a new tab)
  77. Kim et al. (2024) (opens in a new tab)
  78. Kirby et al. (2010) (opens in a new tab)
  79. Krajnc (2015) (opens in a new tab)
  80. Kyle et al. (2018) (opens in a new tab)
  81. Lane et al. (2011) (opens in a new tab)
  82. Laurvick et al. (2006) (opens in a new tab)
  83. Levy-Shraga et al. (2025) (opens in a new tab)
  84. Lotan (2019) (opens in a new tab)
  85. MacKay et al. (2018) (opens in a new tab)
  86. Maheshwari (2018) (opens in a new tab)
  87. Managed Healthcare Executive (2023) (opens in a new tab)
  88. May et al. (2023) (opens in a new tab)
  89. May et al. (2024a) (opens in a new tab)
  90. May et al. (2024b) (opens in a new tab)
  91. May et al. (2024c) (opens in a new tab)
  92. McArthur and Budden (1998) (opens in a new tab)
  93. McGraw et al. (2023) (opens in a new tab)
  94. McKnight et al. (2022) (opens in a new tab)
  95. Montgomery et al. (2026) (opens in a new tab)
  96. Moore et al. (2024) (opens in a new tab)
  97. Motil et al. (2024) (opens in a new tab)
  98. Nemours (2026) (opens in a new tab)
  99. Neul et al. (2008) (opens in a new tab)
  100. Neul et al. (2010) (opens in a new tab)
  101. Neul et al. (2014) (opens in a new tab)
  102. Neul et al. (2015) (opens in a new tab)
  103. Neul et al. (2019) (opens in a new tab)
  104. Neul et al. (2022) (opens in a new tab)
  105. Neul et al. (2023a) (opens in a new tab)
  106. Neul et al. (2023b) (opens in a new tab)
  107. Neul et al. (2023c) (opens in a new tab)
  108. Neul et al. (2026) (opens in a new tab)
  109. Neurogene third quarter 2026 results announcement (2026) (opens in a new tab)
  110. NINDS (opens in a new tab)
  111. Okposo et al. (2023) (opens in a new tab)
  112. Patel et al. (2026) (opens in a new tab)
  113. Percy et al. (2010) (opens in a new tab)
  114. Percy et al. (2024a) (opens in a new tab)
  115. Percy et al. (2024b) (opens in a new tab)
  116. Percy et al. (2025a) (opens in a new tab)
  117. Percy et al. (2025b) (opens in a new tab)
  118. Peron et al. (2022) (opens in a new tab)
  119. Peters et al. (2026) (opens in a new tab)
  120. Petriti et al. (2023) (opens in a new tab)
  121. Pimprikar et al. (2026) (opens in a new tab)
  122. Prange et al. (2026) (opens in a new tab)
  123. Prasad et al. (2022a) (opens in a new tab)
  124. Prasad et al. (2022b) (opens in a new tab)
  125. Pulles et al. (2026) (opens in a new tab)
  126. Quarmley et al. (2026) (opens in a new tab)
  127. Rajagopalan et al. (2025) (opens in a new tab)
  128. Rashid et al. (2025a) (opens in a new tab)
  129. Rashid et al. (2025b) (opens in a new tab)
  130. Rashid et al. (2026a) (opens in a new tab)
  131. Rashid et al. (2026b) (opens in a new tab)
  132. Rashid et al. (2026c) (opens in a new tab)
  133. Raspa et al. (2020) (opens in a new tab)
  134. Rossignol et al. (2023) (opens in a new tab)
  135. Rossignol et al. (2024a) (opens in a new tab)
  136. Rossignol et al. (2024b) (opens in a new tab)
  137. Rossignol et al. (2025a) (opens in a new tab)
  138. Rossignol et al. (2025b) (opens in a new tab)
  139. Rozensztrauch et al. (2021) (opens in a new tab)
  140. Sadhu et al. (2024) (opens in a new tab)
  141. Samanta (2026) (opens in a new tab)
  142. Sarajlija et al. (2015) (opens in a new tab)
  143. Sigafoos et al. (2023) (opens in a new tab)
  144. Singh et al. (2020) (opens in a new tab)
  145. Sinnett et al. (2021) (opens in a new tab)
  146. Skrobanski et al. (2025) (opens in a new tab)
  147. Stallworth et al. (2019) (opens in a new tab)
  148. Stone et al. (2023) (opens in a new tab)
  149. Strugnell et al. (2020) (opens in a new tab)
  150. Symons et al. (2013) (opens in a new tab)
  151. Ta et al. (2022) (opens in a new tab)
  152. Tarquinio et al. (2012) (opens in a new tab)
  153. Tarquinio et al. (2015a) (opens in a new tab)
  154. Tarquinio et al. (2015b) (opens in a new tab)
  155. Tarquinio et al. (2017) (opens in a new tab)
  156. Tarquinio et al. (2018) (opens in a new tab)
  157. Tarquinio et al. (2026) (opens in a new tab)
  158. Tascini et al. (2022) (opens in a new tab)
  159. Taylor et al. (2023) (opens in a new tab)
  160. Taysha Gene Therapies 54th CNS Annual Meeting supplemental analysis announcement (2025) (opens in a new tab)
  161. Taysha Gene Therapies adolescent eligibility announcement (2023) (opens in a new tab)
  162. Taysha Gene Therapies August 2026 corporate presentation (2026) (opens in a new tab)
  163. Taysha Gene Therapies Breakthrough Therapy designation announcement (2025) (opens in a new tab)
  164. Taysha Gene Therapies Catalent commercial manufacturing announcement (2026) (opens in a new tab)
  165. Taysha Gene Therapies clinical program update announcement (2024) (opens in a new tab)
  166. Taysha Gene Therapies European orphan designation announcement (2021) (opens in a new tab)
  167. Taysha Gene Therapies Fast Track designation announcement (2023) (opens in a new tab)
  168. Taysha Gene Therapies first participant dosed announcement (2023) (opens in a new tab)
  169. Taysha Gene Therapies first pediatric participant dosed announcement (2024) (opens in a new tab)
  170. Taysha Gene Therapies first quarter 2026 results announcement (2026) (opens in a new tab)
  171. Taysha Gene Therapies first-cohort data HCP presentation (2024) (opens in a new tab)
  172. Taysha Gene Therapies Form 10-K (2026) (opens in a new tab)
  173. Taysha Gene Therapies full rights announcement (2025) (opens in a new tab)
  174. Taysha Gene Therapies full-year 2024 results announcement (2025) (opens in a new tab)
  175. Taysha Gene Therapies full-year 2025 results announcement (2026) (opens in a new tab)
  176. Taysha Gene Therapies healthcare professionals page (opens in a new tab)
  177. Taysha Gene Therapies June 2026 program update presentation (2026) (opens in a new tab)
  178. Taysha Gene Therapies low dose cohort data announcement (2024) (opens in a new tab)
  179. Taysha Gene Therapies orphan drug and rare pediatric disease designation announcement (2020) (opens in a new tab)
  180. Taysha Gene Therapies our science page (opens in a new tab)
  181. Taysha Gene Therapies pivotal program progress announcement (2026) (opens in a new tab)
  182. Taysha Gene Therapies pivotal trial design announcement (2025) (opens in a new tab)
  183. Taysha Gene Therapies REVEAL pivotal dosing completion announcement (2026) (opens in a new tab)
  184. Taysha Gene Therapies RMAT designation announcement (2024) (opens in a new tab)
  185. Taysha Gene Therapies second quarter 2025 results announcement (2025) (opens in a new tab)
  186. Taysha Gene Therapies second quarter 2026 results announcement (2026) (opens in a new tab)
  187. Taysha Gene Therapies third quarter 2024 results announcement (2024) (opens in a new tab)
  188. Taysha Gene Therapies third quarter 2026 Form 10-Q (2026) (opens in a new tab)
  189. Taysha Gene Therapies third quarter 2026 results announcement (2026) (opens in a new tab)
  190. Townend et al. (2016) (opens in a new tab)
  191. Townend et al. (2020) (opens in a new tab)
  192. Trappe et al. (2001) (opens in a new tab)
  193. Vidal et al. (2017) (opens in a new tab)
  194. Vignoli et al. (2025) (opens in a new tab)
  195. Vilvarajan et al. (2023) (opens in a new tab)
  196. WHO Proposed INN List 130 (2023) (opens in a new tab)
  197. Wiedemann et al. (2019) (opens in a new tab)
  198. Wong et al. (2018) (opens in a new tab)
  199. Young et al. (2007) (opens in a new tab)